Inhibition of hepatocellular carcinoma by PegIFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study

Namiki Izumi,Yasuhiro Asahina,Masayuki Kurosaki,Gotaro Yamada,Tsutomu Kawai,Eiji Kajiwara,Yukishige Okamura,Takayuki Takeuchi,Osamu Yokosuka,Kazuya Kariyama,Joji Toyoda,Mie Inao,Eiji Tanaka,Hisataka Moriwaki,Hiroshi Adachi,Shinji Katsushima,Masatoshi Kudo,Kouichi Takaguchi,Yoichi Hiasa,Kazuaki Chayama,Hiroshi Yatsuhashi,Makoto Oketani,Hiromitsu Kumada
DOI: https://doi.org/10.1007/s00535-012-0641-9
Abstract:Background: We investigated whether the administration of maintenance doses of interferon prevented hepatocellular carcinoma (HCC) in patients with chronic hepatitis C. Methods: Study 1: A multicenter, retrospective, cooperative study was carried out to determine whether long-term administration of low-dose peginterferon alpha-2a (PegIFNα-2a) prevented HCC development in patients with chronic hepatitis C. In total, 594 chronic hepatitis C patients without a history of HCC were enrolled and treated with 90 μg PegIFNα-2a administered weekly or bi-weekly for at least 1 year. Study 2: HCC developed in 16 of 99 additional patients without PegIFNα-2a treatment during 3.8 years of observation. A propensity-matched control study was then carried out to compare the incidence of HCC between the 59 patients who received low-dose PegIFNα-2a (PegIFNα-2a group) and 59 patients who did not receive PegIFNα-2a treatment (control group), matched for sex, age, platelet count, and total bilirubin levels. Results: Study 1: HCC developed in 49 patients. The risk of HCC was lower in patients with undetectable hepatitis C virus RNA, ≤40 IU/L alanine aminotransferase (ALT), or ≤10 ng/L alpha-fetoprotein (AFP) 24 weeks after the start of therapy. Study 2: The incidence of HCC was significantly lower in the PegIFNα-2a group than in the control group. Conclusions: Low-dose and long-term maintenance administration of PegIFNα-2a decreased the incidence of HCC in patients with normalized ALT and AFP levels at 24 weeks compared with patients without normal ALT and AFP levels.
What problem does this paper attempt to address?